Six-membered Hetero Ring Consists Of Oxygen, Sulfur, Nitrogen And Carbon (e.g., Oxathiazines, Etc.) Patents (Class 544/2)
  • Patent number: 10308654
    Abstract: Disclosed are a preparation method for a kinase inhibitor and a use thereof. The kinase inhibitor is a compound represented by formula (I) wherein the groups are defined as described in the description. The compound of formula (I) has a kinase inhibitory activity and therefore can be used for the preparation of medicines for treating kinase activity-related diseases.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: June 4, 2019
    Assignee: CHANGZHOU LONGTHERA PHARMACEUTICALS INC.
    Inventors: Peng Cheng, Wenjie Cao
  • Patent number: 9611226
    Abstract: Disclosed in the present invention is a preparation method of azoxystrobin having a structure as shown by formula (1), the method comprising: a) performing an etherification reaction by reacting the compound having a structure shown by formula (2) with 2-cyanophenol and/or a salt thereof under the catalysis of an azabicyclo tertiary amine compound and/or a salt thereof as the catalyst in a butyl acetate medium to obtain a butyl acetate solution containing azoxystrobin; and b) cooling the butyl acetate solution containing azoxystrobin to precipitate Azoxystrobin having a structure as shown by formula (1) from the butyl acetate solution. Using the method provided by the present invention to prepare azoxystrobin can significantly improve the yield of azoxystrobin, and can obtain azoxystrobin products having high purity.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: April 4, 2017
    Assignees: Nutrichem Company Limited, Shanqyu Nutrichem Co., Ltd.
    Inventors: Wenjun Wang, Jianwei Chen, Jianhong Chi, Yongchang Zhao, Xufang Deng, Long Wang, Hua'nan You
  • Patent number: 9241943
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 26, 2016
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Patent number: 9133343
    Abstract: Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, protein thermal stability shift assay and analysis of molecular chaperone activity. These dyes and compositions are also useful as probes in nucleic acid and protein detection.
    Type: Grant
    Filed: November 30, 2009
    Date of Patent: September 15, 2015
    Assignee: Enzo Biochem, Inc.
    Inventors: Wayne Forrest Patton, Sergiy M. Yarmoluk, Praveen Pande, Vladyslava Kovalska, Lijun Dai, Kateryna Volkova, Jack Coleman, Mykhaylo Losytskyy, Anthony Ludlam, Anatoliy Balanda
  • Patent number: 9024016
    Abstract: In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammonium amidosulfamic acid salt. The first reaction mixture comprises sulfamic acid, an amine, and smaller amounts, if any, acetic acid, e.g., less than 1 wt % (10000 wppm). In terms of ranges, the first reaction mixture may comprise from 1 wppm to 1 wt % acetic acid. The process further comprises the step of reacting the amidosulfamic acid salt with diketene to form an acetoacetamide salt. In preferred embodiments, the amidosulfamic acid salt formation reaction is conducted at pH levels from 5.5 to 7.0. The process further comprises the step of deriving the acesulfame-K from the acetoacetamide salt.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Nutrinova Nutrition Specialists & Food Ingredients GmbH
    Inventors: Michael J. Bayer, Stephan Brietzke, Peter Groer, Christoph Mollenkopf
  • Patent number: 8957211
    Abstract: The disclosure relates to (heterocycle-fused piperidine)-(piperazinyl)-1-alkanone derivatives and (heterocycle-fused pyrrolidine)-(piperazinyl)-1-alkanone derivatives of formula (I): wherein A, W, R2 and n are as defined in the disclosure, to the method of preparation thereof and the therapeutic use thereof.
    Type: Grant
    Filed: October 8, 2013
    Date of Patent: February 17, 2015
    Assignee: Sanofi
    Inventors: Marco Baroni, Francoise Bono, Sandrine Delbary-Gossart, Valentina Vercesi
  • Patent number: 8901114
    Abstract: The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: December 2, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Gerhard Kretzschmar, Kurt Ritter, Georg Tschank
  • Patent number: 8895547
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: November 25, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Patent number: 8871758
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: October 28, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Patent number: 8846666
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable for the treatment of hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: September 30, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Patent number: 8828995
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: September 9, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Patent number: 8828994
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: September 9, 2014
    Assignee: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20140243302
    Abstract: Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.
    Type: Application
    Filed: June 26, 2012
    Publication date: August 28, 2014
    Applicants: MERCK SHARP & DOHME CORPORATION, KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Yasumichi Fukuda, David E. Kaelin, JR., Sheo B. Singh
  • Patent number: 8809324
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: August 19, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Kurt Ritter, Christian Engel, Torsten Haack, Stefan Guessregen, Georg Tschank
  • Patent number: 8809325
    Abstract: Disclosed is a benzyl-oxathiazine derivative, as shown in Formula I, the derivative being substituted with adamantane or noradamantane: the variables of which are as described herein; also disclosed is a method of preparation and use of same.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: August 19, 2014
    Assignee: SANOFI
    Inventors: Thomas Boehme, Kurt Ritter, Christian Engel, Torsten Haack, Stefan Guessregen, Georg Tschank
  • Publication number: 20140221352
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
    Type: Application
    Filed: April 10, 2014
    Publication date: August 7, 2014
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Yan Chen, Vanessa Taylor, Hui Li, Rajinder Singh
  • Publication number: 20140194412
    Abstract: The present invention provides an anticancer drug having a Ras function inhibitory action. The present invention provides a Ras function inhibitor comprising a compound represented by the formula (I?): wherein each symbol is as defined in the present specification, or a salt thereof.
    Type: Application
    Filed: May 9, 2012
    Publication date: July 10, 2014
    Applicants: KNC LABORATORIES CO., LTD., NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Tohru Kataoka, Fumi Shima, Masahiro Neya, Daisuke Sasahara
  • Patent number: 8710050
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Grant
    Filed: March 7, 2012
    Date of Patent: April 29, 2014
    Assignee: Sanofi
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20140066437
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: March 6, 2014
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Patent number: 8637635
    Abstract: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a varirty of cardiovascular diseases as described below. Thus, the present invention provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CRPPR (SEQ ID NO: 1) or a peptidomimetic thereof. The invention further provides an isolated peptide or peptidomimetic which has a length of less than 60 residues and includes the amino acid sequence CARPAR (SEQ ID NO: 5) or a peptidomimetic thereof, or amino acid sequence CPKRPR (SEQ ID NO: 6) or a peptidomimtic thereof.
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: January 28, 2014
    Inventors: Lianglin Zhang, Jason A. Hoffman, Erkki Ruoslahti
  • Publication number: 20140024584
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: January 23, 2014
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20130345127
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Kurt Ritter, Christian Engel, Torsten Haack, Stefan Guessregen, Georg Tschank
  • Publication number: 20130345207
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Kurt Ritter, Christian Engel, Torsten Haack, Stefan Guessregen, Georg Tschank
  • Publication number: 20130345126
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20130345128
    Abstract: The invention relates to the compounds of formula (I) and physiologically acceptable salts thereof. The compounds are suitable, e.g., for treating hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Gerhard Kretzschmar, Kurt Ritter, Georg Tschank
  • Publication number: 20130345125
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 26, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20130338066
    Abstract: The invention relates to the compounds of formula (I) and to the physiologically acceptable salts thereof. Said compounds are suitable e.g. for the treatment of hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 19, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20130338150
    Abstract: The invention relates to compounds of formula (I) and to the physiologically compatible salts thereof. Said compounds are suitable, for example, for treating hyperglycemia.
    Type: Application
    Filed: March 7, 2012
    Publication date: December 19, 2013
    Applicant: SANOFI
    Inventors: Thomas Boehme, Christian Engel, Stefan Guessregen, Torsten Haack, Kurt Ritter, Georg Tschank
  • Publication number: 20130331565
    Abstract: In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammonium amidosulfamic acid salt. The first reaction mixture comprises sulfamic acid, an amine, and smaller amounts, if any, acetic acid, e.g., less than 1 wt % (10000 wppm). In terms of ranges, the first reaction mixture may comprise from 1 wppm to 1 wt % acetic acid. The process further comprises the step of reacting the amidosulfamic acid salt with diketene to form an acetoacetamide salt. In preferred embodiments, the amidosulfamic acid salt formation reaction is conducted at pH levels from 5.5 to 7.0. The process further comprises the step of deriving the acesulfame-K from the acetoacetamide salt.
    Type: Application
    Filed: May 24, 2013
    Publication date: December 12, 2013
    Inventors: Michael J. Bayer, Stephan Brietzke, Peter Groer, Christoph Mollenkopf
  • Publication number: 20130310364
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful.
    Type: Application
    Filed: July 16, 2013
    Publication date: November 21, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Thilo Heckrodt, Yan Chen, Vanessa Taylor, Rajinder Singh, Pingyu Ding, Rose Yen
  • Publication number: 20130116243
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Application
    Filed: December 23, 2010
    Publication date: May 9, 2013
    Applicant: ALMAC DISCOVERY LIMITED
    Inventors: Lixin Zhang, Graham Peter Trevitt, Hugues Miel, Frank Burkamp, Timothy Harrison, Andrew John Wilkinson, Charles-Henry Fabritius
  • Publication number: 20130109656
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: August 15, 2012
    Publication date: May 2, 2013
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Shelley Allen, Ellen Laird, Joseph P. Lyssikatos, John E. Robinson, Christopher P. Corrette, Robert Kirk DeLisle, Walter C. Voegtli
  • Patent number: 8350025
    Abstract: The present invention relates, inter alia, to a process for preparing a compound of formula (I): using a quinuclidine-based catalyst or an optionally 3-substituted N-methyl pryrrolidine-based catalyst.
    Type: Grant
    Filed: October 2, 2007
    Date of Patent: January 8, 2013
    Assignee: Syngenta Limited
    Inventors: Gillan Beveridge, Ewan Campbell Boyd, Jack Hugh Vass, Alan John Whitton
  • Patent number: 8207332
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: July 11, 2011
    Date of Patent: June 26, 2012
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Publication number: 20120142676
    Abstract: Novel derivatives of dihydro-1,4,2-oxathiazine and dihydro-1,4-dithiine oxides, more particularly, novel derivatives of dihydro-1,4,2-oxathiazine and dihydro-1,4-dithiine oxides that target cysteine residues of biomolecules of pharmacological importance are provided as pharmaceutically useful compounds, for example, as anticancer, antiinfectious, antigastric acid secretion, antiosteoporosic, and antiinflammatory agents.
    Type: Application
    Filed: July 27, 2011
    Publication date: June 7, 2012
    Inventors: Gaik-Lean Chee, Walter G. Brouwer, Ewa Osika, Brian B. Hasinoff, A. David Brewer
  • Patent number: 8188269
    Abstract: The present invention relates to improved covalent coupling of two or more entities such as biomolecules, polymer compositions, organic/inorganic molecules/materials, and the like, including their combinations, through one or more novel reactive groups attached to linker groups of 2-1000 atoms length. The present invention also contemplates the use of bifunctional bridge molecules to link two or more entities, wherein the functional groups of the bridge molecules are the novel reactive groups of the present invention.
    Type: Grant
    Filed: May 12, 2008
    Date of Patent: May 29, 2012
    Assignee: Luminex Corporation
    Inventors: Ananda G. Lugade, Kurt D. Hoffacker, Adam J. Jenkins, Karri L. Michael-Ballard, Leonid Patsenker, Ewald Terpetschnig, Veronica D. Thomason, Ralph McDade
  • Patent number: 8182756
    Abstract: The invention discloses a kind of sulfonation cyclization technique for synthesizing acesulfame potassium for continuous production without stirring and special equipment for this technique. An injection pump is adopted to directly inject the sulfonation raw material and sulfonating agent into autoclave for sulfonation cyclization reaction under high velocity. Moreover, the reciprocating pump is adopted to deliver part of materials in autoclave to condenser designed outside the autoclave for cooling, followed by delivering the cooled materials to another input end of injection pump which together with sulfonation raw material and sulfonating agent is injected into autoclave through high-velocity injection by injection pump. The apparatus is composed of autoclave, injection pump, reciprocating pump and condenser.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: May 22, 2012
    Assignee: Suzhou Hope Technology Co., Ltd
    Inventors: Jicai Liu, Lingwen Kong, Zhongxiang Bao, Xiaoping Chen
  • Patent number: 8173641
    Abstract: The present invention relates to novel benzoxathiazine derivatives of the formula (I) in which R1, R2, R3, R4, R5 and R6 are each as defined in the description, to several processes for preparation thereof and to the use thereof as insecticides and/or acaricides in combination with further compositions such as penetrants and/or ammonium or phosphonium salts.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: May 8, 2012
    Assignee: Bayer CropScience AG
    Inventors: Bernd Alig, Klaus-Helmut Müller, Eva-Maria Franken, Ulrich Görgens, Arnd Voerste
  • Publication number: 20120101257
    Abstract: The present application describes general process for the preparation of amino-substituted gamma-lactams involving the reaction of synthons of the general Formulae (I) and (VI): with amines. The processes are amenable to solid phase synthetic techniques and therefore allow the efficient incorporation of amino-substituted gamma-lactams into a wide variety of structural scaffolds, including, in particular peptides.
    Type: Application
    Filed: March 18, 2010
    Publication date: April 26, 2012
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: William Lubell, Andrew Jamieson, Nicolas Boutard, Luisa Ronga, Daniel St-Cyr, Stephane Turcotte, Wang Chen
  • Publication number: 20120094983
    Abstract: A compound of formula I wherein R1, R2, R3, R4 and R5 are described herein.
    Type: Application
    Filed: March 15, 2011
    Publication date: April 19, 2012
    Inventors: James A. Johnson, Yoon Jeon, John Lloyd, Heather Finlay
  • Publication number: 20120041194
    Abstract: The present invention provides nitrogen and sulfur-containing heterocycle compounds to be used as scaffolds and, in particular, nitrogen and sulfur-containing heterocycle compounds having a thiomorpholine core. The compounds herein described may be useful in treating diseases such as diabetes, obesity, cancer, cardiovascular, Alzheimer's, inflammatory, antidepressant, rheumatoid arthritis, multiple sclerosis, allergic rhinitis, asthma as well as viral and bacterial infections. The compounds herein described may also be useful in treating CNS disorders such as but not limited to Schizophrenia, Alzheimer's disease (AD).
    Type: Application
    Filed: August 29, 2009
    Publication date: February 16, 2012
    Applicant: Triad Multitech Pharmaceuticals, Inc.
    Inventor: Murty N. Armilli
  • Patent number: 8105504
    Abstract: Organic materials which possess outstanding stability to oxidative, thermal or light-induced degradation comprise as stabilizers at least one compound of the formula (I) wherein the general symbols are as defined in claim 1. The compounds of formula I are especially useful as stabilizers for protecting polymers and lubricants against oxidative, thermal or light-induced degradation and as scavengers for oxidized developer in color photographic material.
    Type: Grant
    Filed: August 22, 2005
    Date of Patent: January 31, 2012
    Assignee: BASF SE
    Inventors: Michèle Gerster, Peter Nesvadba
  • Publication number: 20120015841
    Abstract: The invention relates to novel cells and cell lines, and methods for making and using them.
    Type: Application
    Filed: February 1, 2010
    Publication date: January 19, 2012
    Applicant: CHROMOCELL CORPORATION
    Inventors: Kambiz Shekdar, Dennis Sawchuk, Purvi Manoj Shah
  • Publication number: 20110318807
    Abstract: Ghrelin O-acyltransferase (GOAT) is inhibited with designed small molecules. Methods comprise contacting the GOAT with an inhibitor and detecting a resultant inhibition.
    Type: Application
    Filed: September 6, 2011
    Publication date: December 29, 2011
    Inventors: Patrick G. Harran, Michael S. Brown, Joseph L. Goldstein, Jin Yang, Tong-Jin Zhao
  • Publication number: 20110245156
    Abstract: Compounds are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 6, 2011
    Applicant: CYTOKINE PHARMASCIENCES, INC.
    Inventor: Thais M. Sielecki-Dzurdz
  • Patent number: 7977476
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: January 3, 2011
    Date of Patent: July 12, 2011
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Publication number: 20110092558
    Abstract: Compounds of formula (I) in which the substituents are as defined in claim 1, are suitable for use as microbiocides.
    Type: Application
    Filed: April 17, 2009
    Publication date: April 21, 2011
    Applicant: SYNGENTA CROP PROTECTION, INC.
    Inventors: Daniel Stierli, Harald Walter, Ramya Rajan
  • Publication number: 20110071141
    Abstract: Condensed-ring aryl compounds of formula (I) and use of the same as a agrochemical for controlling noxious organisms wherein (X)mQ, A, R1, (Y)n and the grouping —W1—W2—W3—W4— are as defined herein.
    Type: Application
    Filed: March 13, 2009
    Publication date: March 24, 2011
    Inventors: Tetsuya Murata, Yasushi Yoneta, Jun Mihara, Kei Domon, Mamoru Hatazawa, Koichi Araki, Eiichi Shimojo, Katsuhiko Shibuya, Teruyuki Ichihara, Ulrich Görgens, Arnd Voerste, Angela Becker, Eva-Maria Franken, Klaus-Helmut Müller
  • Patent number: 7863058
    Abstract: Disclosed are methods of attaching biologically active compounds to a solid surface, comprising modifying the solid surface using triazine chloride and attaching the biologically active compound to the triazine moiety.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: January 4, 2011
    Assignee: Illumina, Inc.
    Inventors: Chanfeng Zhao, Igor Kozlov, Galina Steinberg-Tatman
  • Patent number: RE48464
    Abstract: In one embodiment, the invention relates to processes for producing acesulfame potassium. In one embodiment, the process comprises the step of reacting a first reaction mixture to form an amidosulfamic acid salt such as a trialkyl ammonium amidosulfamic acid salt. The first reaction mixture comprises sulfamic acid, an amine, and smaller amounts, if any, acetic acid, e.g., less than 1 wt % (10000 wppm). In terms of ranges, the first reaction mixture may comprise from 1 wppm to 1 wt % acetic acid. The process further comprises the step of reacting the amidosulfamic acid salt with diketene to form an acetoacetamide salt. In preferred embodiments, the amidosulfamic acid salt formation reaction is conducted at pH levels from 5.5 to 7.0. The process further comprises the step of deriving the acesulfame-K from the acetoacetamide salt.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: March 16, 2021
    Assignee: Celanese Sales Germany GmbH
    Inventors: Michael J. Bayer, Stephan Brietzke, Peter Groer, Christoph Mollenkopf